Please login to the form below

Not currently logged in
Email:
Password:

Cephalon gets green light for cancer pain drug in EU

The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora
The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora.

Effentora, a buccal tablet formulation of fentanyl, which is indicated for the treatment of breakthrough cancer pain (BTCP) can now be marketed in the 27 EU member states as well as Norway and Iceland.

Cephalon, a US-based biopharmaceutical company, is seeking to bolster its standing in the European healthcare market.

Alain Aragues, president of Cephalon Europe, said: "Cephalon continues to build its presence in Europe, the Middle East and Africa, and activities are ongoing to make Effentora available quickly in the EU member countries."

"We are committed to bring new medications to the European markets that address the needs of patients with cancer," he added.

15th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics